General Info
Joel B. Braunstein is the Co-Founder of C2N Diagnostics and Tivorsan Pharmaceuticals. He serves as an angel investor with a track record of investments in health-related startups such as C2N Diagnostics and Tivorsan Pharmaceuticals. His investments range from â¬11.6m to â¬47.5m. He has a geographical preference for health-related ventures. Braunstein’s partnership style involves providing early commercial guidance to life sciences discoveries. He has a professional career in the healthcare and investment sectors, demonstrating a specific focus on fostering innovation in the health industry.
Location: Chicago, Illinois, United States
Country: United States of America
Industries:
Investment Regions:
Investment Stages: pre-seed, seed
angel-individual
Want to start building warm intros with this investor?
🤖 AI Activity Report
Status: low-active
AI Reasoning: Found an investor profile indicating Joel B. Braunstein’s last recorded investment was on January 6, 2011, in which Tivorsan Pharmaceuticals/C2N Diagnostics are mentioned as associated ventures. That date is more than 12 years prior to the reference date, so the appropriate classification is “low-active”.
Angel activity thresholds:
Low Activity – Only known angel investments more than 12 months ago.
Active – Known angel investments between the last 12 and 6 months.
Very Active – Known angel investments in the last 6 months.
Investor Contact
Team Members
Name
Role
Email
LinkedIn
…
…
…
…
…
Investment Regions Map
loading map…
Similar Investors
Other similar investors:
Latest on X (Twitter)
Access all contact details of Joel B. Braunstein
Gain instant access to partner names, verified emails, LinkedIn profiles, and more—all in one place. Dive into their portfolio founders and their LinkedIn information, so you can quickly start your outreach and look for warm intros.
Add custom tags to your investor cards. Label them by investment stage, industry focus, interest level, or any other criteria you want to stay organized.
Trusted by Founders like You
Find your matching investors using AI